Comparative Analysis: ExxonMobil (XOM) vs Dentsply Sirona (XRAY)
Compare: Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA) - 6.34% for XOM vs 6.46% for XRAY
Investing in the stock market often boils down to comparing potential options. In this article, we provide a comparative analysis of ExxonMobil (XOM) and Dentsply Sirona (XRAY), focusing on price growth and earnings dates.
Swing Trading Performances
Our first point of analysis is the performance of Swing Trader for Beginners: Trading in Markets Trending Up (TA&FA) strategy for both stocks. XOM delivered a return of 6.34%, while XRAY slightly outperformed with a return of 6.46%. This shows that both stocks exhibited robust results with this swing trading approach, with XRAY offering marginally superior returns.
Next, we turn our attention to recent price growth. In the past week, XOM's price has decreased by 1.23%, while XRAY experienced a positive price change of 2.39%. This suggests that XRAY demonstrated a stronger performance over this short-term period.
In the broader industry context, the average weekly price growth for all stocks in the Integrated Oil industry (in which XOM operates) was 0.31%, compared to a decline of 0.88% in the Medical Specialties industry (where XRAY resides). However, looking at the longer-term trends, the average monthly and quarterly growth rates reveal a different story. The Integrated Oil industry experienced monthly and quarterly growth rates of 2.22% and 2.14% respectively, while the Medical Specialties industry faced a monthly decline of 0.37% but a strong quarterly growth of 7.41%.
Thus, while XRAY had a more robust weekly performance, the Medical Specialties industry's overall performance is mixed, with a negative monthly growth rate but a high quarterly growth rate. This emphasizes the importance of understanding both individual stock performances and broader industry trends when making investment decisions.
Upcoming Earnings Dates
Lastly, investors should note the upcoming earnings release dates for both companies. XOM is expected to report earnings on July 28, 2023, while XRAY is expected to release earnings a week later, on August 4, 2023. These dates are significant as earnings reports can significantly impact a stock's price and investor sentiment.
When comparing XOM and XRAY, investors need to consider various factors, including trading performance, price growth, and upcoming earnings dates. Both stocks performed well with the swing trading strategy, and XRAY displayed superior short-term price growth. However, investors must also consider the mixed industry performance, especially for XRAY. It's vital to monitor these factors and others to make informed decisions.
XOM broke above its upper Bollinger Band on September 01, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 41 similar instances where the stock broke above the upper band. In of the 41 cases the stock fell afterwards. This puts the odds of success at .
The 10-day RSI Indicator for XOM moved out of overbought territory on September 15, 2023. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 67 cases where XOM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XOM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Momentum Indicator moved above the 0 level on August 29, 2023. You may want to consider a long position or call options on XOM as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for XOM just turned positive on August 30, 2023. Looking at past instances where XOM's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .
The 50-day moving average for XOM moved above the 200-day moving average on September 14, 2023. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XOM advanced for three days, in of 333 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 255 cases where XOM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. XOM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: XOM's P/B Ratio (2.331) is slightly higher than the industry average of (1.121). P/E Ratio (9.311) is within average values for comparable stocks, (17.108). Projected Growth (PEG Ratio) (1.768) is also within normal values, averaging (4.065). Dividend Yield (0.031) settles around the average of (0.101) among similar stocks. P/S Ratio (1.340) is also within normal values, averaging (1.245).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a distributer of crude oil, natural gas and petroleum products
A.I.dvisor indicates that over the last year, XOM has been closely correlated with CVX. These tickers have moved in lockstep 88% of the time. This A.I.-generated data suggests there is a high statistical probability that if XOM jumps, then CVX could also see price increases.